(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology...
Stats | |
---|---|
Šios dienos apimtis | 114 913 |
Vidutinė apimtis | 109 219 |
Rinkos kapitalizacija | 53.79M |
EPS | $0 ( 2024-03-19 ) |
Kita pelno data | ( $0 ) 2024-06-12 |
Last Dividend | $0.0470 ( 1995-06-29 ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.23 |
ATR14 | $0.00300 (0.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-23 | Cannon Kara | Buy | 150 000 | Common Stock |
2024-02-21 | Cannon Kara | Buy | 10 640 | Common Stock |
2024-02-21 | Cannon Kara | Sell | 5 823 | Common Stock |
2024-02-23 | Eckert Patricia | Buy | 75 000 | Stock Option (to acquire shares of Common Stock) |
2024-01-31 | Pully Steven J | Buy | 79 365 | Common Stock |
INSIDER POWER |
---|
88.53 |
Last 85 transactions |
Buy: 4 325 861 | Sell: 177 248 |
Tūris Koreliacija
Enzo Biochem Inc Koreliacija
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
FPEI | -0.872 |
ASB-PE | -0.868 |
CUBB | -0.868 |
GL | -0.855 |
FLR | -0.852 |
NX | -0.843 |
MBI | -0.836 |
PQDI | -0.832 |
BGSF | -0.832 |
SPNT-PB | -0.825 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Enzo Biochem Inc Koreliacija - Valiuta/Žaliavos
Enzo Biochem Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $31.06M |
Bruto pelnas: | $11.57M (37.24 %) |
EPS: | $-1.270 |
FY | 2023 |
Pajamos: | $31.06M |
Bruto pelnas: | $11.57M (37.24 %) |
EPS: | $-1.270 |
FY | 2022 |
Pajamos: | $107.07M |
Bruto pelnas: | $41.97M (39.20 %) |
EPS: | $-0.460 |
FY | 2021 |
Pajamos: | $117.73M |
Bruto pelnas: | $53.58M (45.51 %) |
EPS: | $0.160 |
Financial Reports:
No articles found.
Enzo Biochem Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0470 | 1995-06-29 |
Last Dividend | $0.0470 | 1995-06-29 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.0470 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.82 | -- |
Div. Sustainability Score | 5.02 | |
Div.Growth Potential Score | 0.366 | |
Div. Directional Score | 2.69 | -- |
Year | Amount | Yield |
---|---|---|
1995 | $0.0470 | 0.58% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
NCZ | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.79% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
SRV | Dividend Royal | 2023-12-04 | Monthly | 18 | 7.53% | 8.50 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 2.58 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.333 | 1.200 | 10.00 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.545 | 1.500 | 5.06 | 7.59 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.20 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.78 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.58 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0444 | -1.500 | 9.26 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 33.77 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.879 | 2.00 | -0.293 | -0.586 | [0 - 30] |
freeCashFlowPerShareTTM | -0.909 | 2.00 | -0.455 | -0.909 | [0 - 20] |
debtEquityRatioTTM | 0.0621 | -1.500 | 9.75 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -1.203 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.348 | 1.000 | -8.96 | -8.96 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -10.10 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.129 | 0.800 | -2.47 | -1.977 | [0.5 - 2] |
Total Score | 5.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 1.605 | 1.000 | 9.94 | 0 | [1 - 100] |
returnOnEquityTTM | 0.545 | 2.50 | 6.82 | 7.59 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.909 | 2.00 | -0.303 | -0.909 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.879 | 2.00 | -0.293 | -0.586 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.00912 | 1.500 | -3.39 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -3.47 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | 0.366 |
Enzo Biochem Inc
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.